Zhou GG - Search Results

1

Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12.

Wang L, Zhou X, Chen X, Liu Y, Huang Y, Cheng Y, Ren P, Zhao J, Zhou GG. Wang L, et al. Among authors: zhou gg. Mol Ther Oncol. 2024 Apr 6;32(2):200799. doi: 10.1016/j.omton.2024.200799. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38681801 Free PMC article.

2

Chemical constituents from the roots of Dolomiaea souliei.

Wang Z, Zhang LD, Zhou GG, Zhong QZ, Jiang YB, Wang GW, Liao ZH, Meng FC, Chen M. Wang Z, et al. Among authors: zhou gg. Nat Prod Res. 2023 Jun 6:1-9. doi: 10.1080/14786419.2023.2215902. Online ahead of print. Nat Prod Res. 2023. PMID: 37282630

3

Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models.

Wu Y, Chen X, Wang L, Zhou X, Liu Y, Ji D, Ren P, Zhou GG, Zhao J. Wu Y, et al. Among authors: zhou gg. Viruses. 2022 Dec 15;14(12):2796. doi: 10.3390/v14122796. Viruses. 2022. PMID: 36560800 Free PMC article.

4

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy.

Liu Y, Zheng Y, Deng T, Huang Y, Liu Z, Zhan B, Zhou X, Yan R, Ren J, Xing Y, Wu G, Zheng B, Hu G, Wang W, Liu Y, Zhao J, Chen X, Zhou GG. Liu Y, et al. Among authors: zhou gg. Front Oncol. 2022 Oct 24;12:1037934. doi: 10.3389/fonc.2022.1037934. eCollection 2022. Front Oncol. 2022. PMID: 36353540 Free PMC article.

5

USP18 and USP20 restrict oHSV-1 replication in resistant human oral squamous carcinoma cell line SCC9 and affect the viability of SCC9 cells.

Lu R, Wu G, Chen M, Ji D, Liu Y, Zhou GG, Fu W. Lu R, et al. Among authors: zhou gg. Mol Ther Oncolytics. 2021 Nov 11;23:477-487. doi: 10.1016/j.omto.2021.11.004. eCollection 2021 Dec 17. Mol Ther Oncolytics. 2021. PMID: 34901390 Free PMC article.

6

High accumulation of Mx2 renders limited multiplication of oncolytic herpes simplex virus-1 in human tumor cells.

Ren Y, Chen M, Wu G, Ji D, Zhou GG, Ren PG, Fu W. Ren Y, et al. Among authors: zhou gg. Sci Rep. 2021 Oct 27;11(1):21227. doi: 10.1038/s41598-021-00691-y. Sci Rep. 2021. PMID: 34707174 Free PMC article.

7

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.

Zhou X, Zhao J, Zhang JV, Wu Y, Wang L, Chen X, Ji D, Zhou GG. Zhou X, et al. Among authors: zhou gg. Viruses. 2021 Sep 3;13(9):1758. doi: 10.3390/v13091758. Viruses. 2021. PMID: 34578339 Free PMC article.

8

Identification of Rab27a as a host factor for oncolytic herpes virus susceptibility to tumor cells.

Zhou X, Zhao J, Wu Y, Wang L, Ji D, Chen X, Ren P, Zhou GG. Zhou X, et al. Among authors: zhou gg. Virus Res. 2021 Jul 2;299:198425. doi: 10.1016/j.virusres.2021.198425. Epub 2021 Apr 26. Virus Res. 2021. PMID: 33905773

9

Author Correction: VHS, US3 and UL13 viral tegument proteins are required for Herpes Simplex Virus-Induced modification of protein kinase R.

Pennisi R, Musarra-Pizzo M, Lei Z, Zhou GG, Sciortino MT. Pennisi R, et al. Among authors: zhou gg. Sci Rep. 2021 Mar 30;11(1):7503. doi: 10.1038/s41598-021-87273-0. Sci Rep. 2021. PMID: 33785828 Free PMC article. No abstract available.

10

IFNgamma-inducible CXCL10/CXCR3 axis alters the sensitivity of HEp-2 cells to ionizing radiation.

Lin Y, Lu R, Hou J, Zhou GG, Fu W. Lin Y, et al. Among authors: zhou gg. Exp Cell Res. 2021 Jan 1;398(1):112382. doi: 10.1016/j.yexcr.2020.112382. Epub 2020 Nov 28. Exp Cell Res. 2021. PMID: 33253709

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page